A Phase 1/2 interventional study of Isatuximab SAR650984 and Dexamethasone in Hematological Malignancy, sponsored by Sanofi. Completed at 59 sites in 17 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-01.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.
Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 40th largest by enrollment of the 658 interventional ones that give a count, is one of 23 that started in 2010, is one of 81 in phase 1/2, and was the 156th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Orum Therapeutics USA, Inc. · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
821 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 276 · Phase 2 280 · Phase 3 43 · Phase 4 9
First in 1989; this study’s year is marked. 23 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 351 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 40 across the 658 interventional studies, 150 across the 157 observational. Of the 497 that completed or were terminated, 208 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 821 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 2 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
90 of the studies in Hematologic Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT04188418Phase 3M.D. Anderson Cancer CenterFentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients | 2027-08-31 |
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT02203903Catherine BollardMulti-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies | 2026-11-30 |
Add all 90 to your calendar (.ics) → With an account.
Among the 821 studies in Hematologic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Phase 1:
To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
Phase 2 (stage 1):
To evaluate the activity of single-agent Isatuximab at different doses/schedules and to select dose and regimen to further evaluate the overall response rate (ORR) of Isatuximab as single agent or in combination with dexamethasone.
Phase 2 (stage 2):
To evaluate the activity in terms of overall response rate (ORR) of Isatuximab at the selected dose/schedule from stage1, as single agent (ISA arm) and in combination with dexamethasone (ISAdex arm).
Secondary Objectives:
Phase 1:
Phase 2 (stage 1): to evaluate the following objectives for Isatuximab as single agent:
Phase 2 (stage 2): to evaluate the following objectives in each arm (ISA and ISAdex):
The Phase 1 study duration for an individual participant included a screening period for inclusion of up to 2 weeks, treatment with Isatuximab QW (every week) or Q2W (every 2 weeks) unless discontinued earlier due to safety or disease progression. Participants were followed for a minimum of 30 days following the last use of study drug or more than 30 days in case of unresolved toxicity, or up to initiation of another anticancer treatment.
The Phase 2 study duration for an individual participant included a screening period for inclusion of up to 3 weeks, then a treatment period and a follow up period. Treatment was continued until disease progression, unacceptable adverse reactions or other reasons for discontinuation. Participants were followed every 3 months following the last use of study drug until death or study cutoff, whichever came first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 1:
Phase 2:
Exclusion criteria:
Phase 1:
Phase 2:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with CD38+ hematological malignancies (HM), received Isatuximab at any one of the dose less than or equal to (\<=) 1 milligram per kilogram (mg/kg) (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as intravenous (IV) infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
Drug: Isatuximab SAR650984
Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
Drug: Isatuximab SAR650984
Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
Drug: Isatuximab SAR650984
Participants with CD38+ HM along with participants with standard risk multiple myeloma were included this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
Drug: Isatuximab SAR650984
Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
Drug: Isatuximab SAR650984
Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
Drug: Isatuximab SAR650984
Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
Drug: Isatuximab SAR650984
Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
Drug: Isatuximab SAR650984
Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable adverse event (AE), disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).
Drug: Isatuximab SAR650984
Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).
Drug: Isatuximab SAR650984
Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 week (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).
Drug: Isatuximab SAR650984
Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 92 weeks).
Drug: Isatuximab SAR650984
Participants with relapsed or relapsed/refractory multiple myeloma (RRMM), received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 301 weeks).
Drug: Isatuximab SAR650984
Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for less than \[\<\] 75 years of age; 20 mg/day \[greater than or equal to \[\>=\] for 75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 301 weeks).
Drug: Isatuximab SAR650984 · Drug: Dexamethasone
Pharmaceutical form: solution for infusion Route of administration: intravenous
Also known as: Sarclisa
Pharmaceutical form: solution for infusion Route of administration: intravenous
Pharmaceutical form: tablet Route of administration: oral
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
DLTs were assessed using the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03. DLTs were defined as any Grade 3 or higher non-hematological toxicity (with the exception of allergic reaction/hypersensitivity), Grade 4 neutropenia and/or Grade 4 thrombocytopenia lasting longer than 5 days, attributed to isatuximab. Any other toxicity that the Investigator and the Sponsor deemed to be dose-limiting, regardless of the grade, was also considered as DLT.
Time frame: Day 1 of Cycle 1 up to Day 14 of Cycle 2
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.
Time frame: From Baseline up to 30 days after the last dose (maximum duration: 120 weeks )
Phase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria
OR defined as participants with stringent complete response (sCR) or complete response (CR) or very good partial response (VGPR) or partial response (PR) . Based on IMWG, CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; sCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; PR: \>=50% reduction of serum M-Protein and reduction in urinary M-protein by \>=90% or to \<200 mg/24 hours; \>=50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a \>=50% reduction in plasma cells in place of M-protein if present at baseline.
Time frame: From the date of randomization until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for Stage 1b arm)
Phase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria
OR: participants with sCR or CR or VGPR or PR. As per updated IMWG, CR: Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; normal FLC ratio of 0.26-1.65 in participants with only FLC disease; sCR: CR and normal FLC ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours, \>90% decrease in the difference between involved and uninvolved FLC levels; PR: \>=50% reduction of serum M-Protein and reduction in urinary M-protein by \>=90% or to \<200 mg/24 hours; \>=50% decrease in the difference between involved and uninvolved FLC levels in place of M-protein criteria or \>=50% reduction in plasma cells in place of M-protein if present at baseline.
Time frame: From the date of randomization to date of death from any cause (maximum duration: 97 weeks)
Pharmacokinetic (PK) Assessment: Phase 1: Plasma Concentration of Isatuximab Observed at the End of an Intravenous Infusion (Ceoi)
Ceoi was defined as the plasma concentration of Isatuximab at end of infusion. Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population: participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter.
Time frame: Cycle 1 Day 1 and Cycle 3 Day 1: At the end of infusion
PK Assessment: Phase 1: Maximum Observed Plasma Concentration (Cmax) of Isatuximab
Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population.
Time frame: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
PK Assessment: Phase 1: Time to Reach Maximum Plasma Concentration Observed (Tmax) of Isatuximab
Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population.
Time frame: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
PK Assessment: Phase 1: Plasma Concentration of Isatuximab at Week 1, 2 and 3
Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).
Time frame: Week 1, 2 and 3
PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First Week (0-168 Hours) (AUC1W)
Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).
Time frame: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First 2 Weeks (0-336 Hours) (AUC2W)
Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).
Time frame: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 336 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 336 hr post-infusion
Pharmacodynamic (PD) Assessment: Phase 1: Change From Baseline in Serum/Plasma Markers
Serum/plasma markers included: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1-β), interleukin 6 (IL-6) and interferon-gamma (IFN-Gamma). Due to change in planned analysis, data for high-sensitivity C-reactive protein (hs-CRP) and CD38 was not collected and analyzed.
Time frame: Cycle 1 Day 1
Immunogenicity Assessment: Phase 1: Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response
ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 1) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.
Time frame: Up to 120 weeks
Clinical Assessment: Phase 1: Percentage of Participants With Overall Response and Clinical Benefit: Assessed Using European Society for Blood and Marrow Transplantation (EBMT) Criteria
OR defined as participants with complete response (CR) or partial response (PR) as best overall response (BOR). Clinical benefit: participants with minimal response (MR) or better as BOR. BOR: best sequential response from start of treatment through the entire study excluding any time point following start of other treatment. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates, no increase in size or number of lytic bone lesions. PR: \>=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. MR: 25 to 49% reduction in serum M-protein, 50-89% reduction in 24h urine M-protein, 25-49% reduction in size of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.
Time frame: From the date of randomization to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)
Clinical Assessment: Phase 1: Duration of Response (DOR)
DOR: time from first response (PR or better) to first documented tumor progression/death. Progression as per EBMT: \>25% increase in serum monoclonal paraprotein level, which must also be an absolute increase of \>= 5 g/l: confirmed by \>=1 repeated investigation; \>25% increase in 24h urinary light chain excretion, which must also be an absolute increase of \>=200 mg/24 h:confirmed by \>=1 repeated investigation; \>25% increase in plasma cells in a bone marrow aspirate/on trephine biopsy, which must also be an absolute increase of \>= 10%; definite increase in size of existing bone lesions/soft tissue plasmacytomas; development of new bone lesions/soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \>11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause. PR: \>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size/number of lytic bone lesions.
Time frame: From the date of first response to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)
Clinical Assessment: Phase 1: Time to First Response (TTR)
TTR was defined as the time from first dose of isatuximab to first response (PR or better). PR: \>=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.
Time frame: From the date of first dose administration to the date of first response or death (due to any cause) (maximum duration: 120 weeks)
Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (Karnofsky Performance Status)-Shift From Baseline Value to Best Value During Treatment
ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest \<50% of waking hours; 3=Bed rest/sitting \>50% of waking hours; 4=Bedridden or unable to care for self, where lower score indicated good performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the best values (categorized as: Baseline ECOG 1, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 1) are reported.
Time frame: At baseline, during treatment (Day 1 up to 120 weeks)
Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group Performance Status (Karnofsky Performance Status)-Shift From Baseline Value to Worst Value During Treatment
ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest \<50% of waking hours; 3=Bed rest/sitting\>50% of waking hours; 4=Bedridden or unable to care for self, where higher score indicated worst performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the worst values (categorized as: Baseline ECOG 0, During Treatment ECOG 1; Baseline ECOG 2, During Treatment ECOG 1; Baseline ECOG 0, During Treatment ECOG 2; Baseline ECOG 1, During Treatment ECOG 2; Baseline ECOG 0, During Treatment ECOG 3; Baseline ECOG 1, During Treatment ECOG 3; Baseline ECOG 2, During Treatment ECOG 3) are reported.
Time frame: At baseline, during treatment (up to 120 weeks)
Phase 2 Stage 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.
Time frame: From Baseline up to 30 days after the last dose (maximum duration: 414 weeks for Stage 1a and 92 weeks for Stage 1b)
Phase 2 Stage 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.
Time frame: From Baseline up to 30 days after the last dose (maximum duration: 301 weeks)
Phase 2 Stage 1: Duration of Response
DOR:Time from date of 1st IAC determined response (\>= PR) that was subsequently confirmed, to date of first IAC determined PD/death, whichever happened earlier. updated IMWG criteria- PR:\>=50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or a \>=50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a \>=50% reduction in size of soft tissue plasmacytomas; PD: Increase of 25% from lowest response value in any of following: Serum M-protein \>=0.5 g/dL absolute increase and/or urine M-protein \>=200 mg/24 hours absolute increase and/or \>10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, \>=10% bone marrow plasma cells (PCs), development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium \>11·5 mg/dl) attributed to PC proliferation disorder.
Time frame: From the date of first response until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Phase 2 Stage 2: Duration of Response
DOR: Time from date of 1st IAC determined response (\>= PR) that was subsequently confirmed, to date of 1st IAC determined PD or death, whichever happened earlier. As per updated IMWG criteria-PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. ≥50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline ≥50% reduction in size of soft tissue plasmacytomas; PD: Increase of \>25% from lowest response value in any one of following: Serum M-component (absolute increase must be \>0.5 g/dL)4 and/or Urine M-component (absolute increase must be \>200 mg/24 h) and/or \>10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, \>=10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to plasma cell proliferative disorder.
Time frame: From the date of first response until disease progression or death or data cut-off (maximum duration: 97 weeks)
Phase 2 Stage 1: Percentage of Participants With Clinical Benefit
Clinical benefit: participants with sCR, CR, VGPR, PR or MR as per IMWG criteria, determined by IAC. CR: negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytomas,\<5% PCs in bone marrow aspirates. sCR: CR + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum \& urine M-component detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-component plus urine M-component level \<100mg/24hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours, ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline, ≥50% size reduction in soft tissue plasmacytomas. MR:\>=25 but \<49% reduction in serum M-protein, reduction in 24h urine M-protein by 50-89%, 25-49% size reduction in soft tissue plasmacytomas.
Time frame: From the date of randomization to the date of first documentation of progression or death (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Phase 2 Stage 2: Percentage of Participants With Clinical Benefit
Clinical benefit:participants with sCR, CR, VGPR, PR or MR, per IMWG criteria, determined by IAC. CR:negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates,normal FLC ratio(0.26-1.65) in participants with only FLC disease.sCR:CR+normal FLC ratio, absence of clonal cells in bone marrow biopsy.VGPR:serum \& urine M-component detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-component plus urine M-component level \<100mg/24h/,\>=90% decrease in difference between involved and uninvolved FLC levels; PR:\>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90%/\<200mg/24h,\>50% decrease in difference between involved and uninvolved FLC in place of M-protein criteria, \>=50% reduction in size/number of soft tissue plasmacytomas. MR:\>=25 but \<49% reduction in serum M-protein,reduction in 24h urine M-protein by 50-89%, 25-49% reduction in size of soft tissue plasmacytomas
Time frame: From the date of randomization to the date of first documentation of progression or death (maximum duration: 97 weeks )
Phase 2 Stage 1: Progression Free Survival (PFS)
PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression (PD) or date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of \> 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be \> 0.5 g/dL), Urine M-component and/or (the absolute increase must be \> 200 mg/24 h), \> 10mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, \>10% absolute percentage of bone marrow plasma cell, definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.
Time frame: From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Phase 2 Stage 2: Progression Free Survival
PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression or the date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of \>25% from lowest response value in any one of the following: Serum M-component (the absolute increase must be \>0.5 g/dL)4 and/or Urine M-component (the absolute increase must be \>200 mg/24 h) and/or \>10 mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, ≥10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.
Time frame: From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 97 weeks)
Phase 2 Stage 1: Overall Survival (OS)
OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.
Time frame: From the date of randomization to date of death from any cause (maximum duration 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Phase 2 Stage 2: Overall Survival
OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.
Time frame: From the date of randomization to date of death from any cause (maximum duration: 97 weeks)
Phase 2 Stage 1: Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scores: Global Health Status
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) \& other single items. For each item, high score = high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.
Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and End of Treatment (EOT: anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Phase 2 Stage 1: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20) Scores: Disease Symptom Subscale Score
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with MM. It has 4 subscales: body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). Disease symptoms subscale used 4-point scale ranged from 1= 'Not at All' to 4= 'Very Much'. Scores were averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL.
Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Phase 2 Stage 1: Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D) Generic Health Status - Visual Analogue Scale Scores
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.
Time frame: Baseline, Day 1 of Cycles 4, 7, 10, 13, 16, 19, and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 1 Week Interval
Time frame: Pre-dose, at the end of infusion, 1 hour and 168 hours post dose on Day 1 of Cycle 1
Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 2 Weeks Interval
Time frame: Cycle 1, Day 1: pre-dose, at the end of infusion, 168 and 336 hours post-infusion
Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 4 Weeks Interval
Time frame: Cycle 1, Day 1: pre-dose, at the end of infusion, 168, 336, and 672 hours post-infusion
Pharmacokinetic Assessment: Phase 2 Stage 2: Plasma Concentration of Isatuximab Before Treatment Administration (Ctrough)
Time frame: At Days 7, 14 and 28
Pharmacokinetic Assessment: Phase 2 Stage 2: Accumulation Ratio of Isatuximab Based on Ctrough
Ctrough is the plasma concentration observed before treatment administration. For 1st category, the accumulation ratio was calculated by dividing Ctrough value of Cycle 2 Day 1 by Cycle 1 Day 8 and for second category, accumulation ratio was calculated by dividing Ctrough value of Cycle 4 Day 1 by Cycle 1 Day 8.
Time frame: Cycle 2, Day 1; Cycle 1, Day 8; Cycle 4, Day 1
Immunogenicity Assessment: Phase 2 Stage 2: Number of Participants With Anti-drug Antibodies to Isatuximab
ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 2 Stage 2) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.
Time frame: Up to 97 weeks
Study participants were involved in the study from 11 May 2010 at 59 centers in 18 countries. A total of 418 participants were screened, of which 351 participants were enrolled. A total of 67 participants had screen failures due to failure to meet inclusion criteria.
| Milestone | Phase1: Isatuximab <=1 mg/kg Every 2 Weeks (Q2W) | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5 mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10 mg/kg Every Week (QW) | Phase 1: Isatuximab 20 mg/kg Q2W | Phase 1: Isatuximab 20 mg/kg QW | Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 6 | 3 | 26 | 18 | 6 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| All treated (at) population | 16 | 6 | 3 | 26 | 18 | 6 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 16 | 6 | 3 | 26 | 18 | 6 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase1: Isatuximab <=1 mg/kg Every 2 Weeks (Q2W) | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5 mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10 mg/kg Every Week (QW) | Phase 1: Isatuximab 20 mg/kg Q2W | Phase 1: Isatuximab 20 mg/kg QW | Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 24 | 25 | 25 | 0 | 0 |
| At population | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 24 | 25 | 25 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 24 | 25 | 25 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase1: Isatuximab <=1 mg/kg Every 2 Weeks (Q2W) | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5 mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10 mg/kg Every Week (QW) | Phase 1: Isatuximab 20 mg/kg Q2W | Phase 1: Isatuximab 20 mg/kg QW | Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 110 | 55 |
| At population | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 109 | 55 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 109 | 55 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Enrolled, but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
DLTs were assessed using the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03. DLTs were defined as any Grade 3 or higher non-hematological toxicity (with the exception of allergic reaction/hypersensitivity), Grade 4 neutropenia and/or Grade 4 thrombocytopenia lasting longer than 5 days, attributed to isatuximab. Any other toxicity that the Investigator and the Sponsor deemed to be dose-limiting, regardless of the grade, was also considered as DLT.
| Participants | Phase 1:Isatuximab <=1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab 10 mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|
| Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.
| Participants | Phase 1: Isatuximab <=1mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10 mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|
| Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 16 | 6 | 3 | 26 | 18 | 6 | 7 | 6 |
OR defined as participants with stringent complete response (sCR) or complete response (CR) or very good partial response (VGPR) or partial response (PR) . Based on IMWG, CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; sCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; PR: \>=50% reduction of serum M-Protein and reduction in urinary M-protein by \>=90% or to \<200 mg/24 hours; \>=50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a \>=50% reduction in plasma cells in place of M-protein if present at baseline.
| percentage of participants | Phase 2 Stage 1a: Isatuximab 3 mg/kg | Phase 2 Stage 1a: Isatuximab 10 mg/kg | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W and Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W |
|---|---|---|---|---|
| Phase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria | 4.3 | 29.2 | 20.0 | 24.0 |
OR: participants with sCR or CR or VGPR or PR. As per updated IMWG, CR: Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; normal FLC ratio of 0.26-1.65 in participants with only FLC disease; sCR: CR and normal FLC ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours, \>90% decrease in the difference between involved and uninvolved FLC levels; PR: \>=50% reduction of serum M-Protein and reduction in urinary M-protein by \>=90% or to \<200 mg/24 hours; \>=50% decrease in the difference between involved and uninvolved FLC levels in place of M-protein criteria or \>=50% reduction in plasma cells in place of M-protein if present at baseline.
| percentage of participants | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Phase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria | 23.9 | 43.6 |
Ceoi was defined as the plasma concentration of Isatuximab at end of infusion. Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population: participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter.
| microgram per milliliter (mcg/mL) | Phase 1: Isatuximab 0.3 mg/kg Q2W | Phase 1: Isatuximab 1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2.08667 ± 0.65567 | 13.18333 ± 5.74464 | 44.22500 ± 15.30651 | 125.50000 ± 53.03301 | 171.43333 ± 50.18853 | 148.80000 ± 18.48513 | 400.33333 ± 52.51984 | 173.33333 ± 20.64784 | 334.33333 ± 98.28462 |
| Cycle 3 Day 1 | — | — | — | — | — | — | — | 299.82500 ± 220.83898 | 715.33333 ± 188.01241 |
Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population.
| mcg/mL | Phase 1: Isatuximab 0.3 mg/kg Q2W | Phase 1: Isatuximab 1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2.00 ± 31 | 12.4 ± 45 | 53.7 ± 28 | 126 ± NA | 181 ± 48 | 154 ± 13 | 457 ± 28 | 181 ± 20 | 343 ± 29 |
| Cycle 3 Day 1 | — | — | — | — | — | — | — | 265 ± 67 | 712 ± 27 |
Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow). Analysis was performed on PK population.
| hours | Phase 1: Isatuximab 0.3 mg/kg Q2W | Phase 1: Isatuximab 1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2.49 (1.42 to 3.43) | 4.35 (3.13 to 6.33) | 6.99 (4.58 to 8.00) | 7.65 (5.13 to 10.17) | 4.28 (2.15 to 9.37) | 4.92 (2.60 to 30.08) | 5.87 (5.78 to 9.90) | 2.25 (2.20 to 7.50) | 6.83 (3.98 to 10.53) |
| Cycle 3 Day 1 | — | — | — | — | — | — | — | 4.30 (2.57 to 27.48) | 8.07 (2.87 to 29.03) |
Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).
| mcg/mL | Phase 1: Isatuximab 1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10 mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 0.00223 ± 86 | 1.44 ± 85 | 15.3 ± 90 | 27.6 ± 81 | 44.2 ± 52 | 20.7 ± 63 | 113 ± 37 | 108 ± 33 |
| Week 2 | 0.000800 ± 173 | 0.181 ± 136 | 1.39 ± 116 | 1.97 ± 145 | 8.31 ± 77 | 55.1 ± 63 | 63.9 ± 46 | 194.8 ± 36 |
| Week 3 | 0.000283 ± 145 | 0.460 ± 121 | 42.7 ± 73 | 4.18 ± 133 | 18.6 ± 71 | 75.9 ± 78 | 91.0 ± 52 | 347.3 ± 36 |
Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).
| mcg*hour/mL | Phase 1: Isatuximab 1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|
| PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First Week (0-168 Hours) (AUC1W) | 222 ± 80 | 2624 ± 24 | 7174 ± 54 | 11566 ± 48 | 13480 ± 38 | 12680 ± 35 | 32739 ± 28 | 28405 ± 27 |
Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab \<=1mg/kg in participant flow).
| mcg*hour/mL | Phase 1: Isatuximab 1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|
| PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First 2 Weeks (0-336 Hours) (AUC2W) | 222 ± 80 | 3076 ± 35 | 9546 ± 70 | 14876 ± 64 | 18967 ± 44 | 30187 ± 40 | 48003 ± 31 | 71174 ± 29 |
Serum/plasma markers included: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1-β), interleukin 6 (IL-6) and interferon-gamma (IFN-Gamma). Due to change in planned analysis, data for high-sensitivity C-reactive protein (hs-CRP) and CD38 was not collected and analyzed.
| picogram/milliliter (pg/mL) | Phase 1:Isatuximab <=1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|
| TNF alpha | 163.181 ± 253.373 | 179.783 ± 191.455 | 352.974 ± 220.394 | 340.799 ± 341.100 | 503.462 ± 479.813 | 342.664 ± 410.245 | 307.319 ± 398.025 | 412.541 ± 243.169 |
| IL-1 Beta | 64.577 ± 227.399 | 29.741 ± 55.515 | 7.527 ± 8.118 | 299.058 ± 572.260 | 547.770 ± 1454.175 | 327.957 ± 759.305 | 305.914 ± 621.754 | 293.307 ± 612.746 |
| IL-6 | 139.234 ± 212.385 | 261.732 ± 270.119 | 73.899 ± 53.211 | 148.594 ± 175.719 | 173.004 ± 433.297 | -8.109 ± 45.845 | 274.616 ± 234.752 | 165.295 ± 203.451 |
| IFN Gamma | 477.116 ± 1673.063 | 5.376 ± 9.312 | 25.806 ± 44.698 | 445.772 ± 1043.982 | 568.806 ± 1022.000 | 627.089 ± 1527.647 | 448.387 ± 569.499 | 1487.097 ± 2693.826 |
ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 1) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.
| Participants | Phase 1:Isatuximab <=1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|
| Treatment-induced ADA | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Treatment boosted ADA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OR defined as participants with complete response (CR) or partial response (PR) as best overall response (BOR). Clinical benefit: participants with minimal response (MR) or better as BOR. BOR: best sequential response from start of treatment through the entire study excluding any time point following start of other treatment. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates, no increase in size or number of lytic bone lesions. PR: \>=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. MR: 25 to 49% reduction in serum M-protein, 50-89% reduction in 24h urine M-protein, 25-49% reduction in size of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.
| percentage of participants | Phase 1: Isatuximab 1mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|---|
| OR | 33.3 | 0 | 33.3 | 28.0 | 16.7 | 33.3 | 14.3 | 28.6 |
| Clinical benefit | 33.3 | 20.0 | 33.3 | 28.0 | 27.8 | 33.3 | 28.6 | 42.9 |
DOR: time from first response (PR or better) to first documented tumor progression/death. Progression as per EBMT: \>25% increase in serum monoclonal paraprotein level, which must also be an absolute increase of \>= 5 g/l: confirmed by \>=1 repeated investigation; \>25% increase in 24h urinary light chain excretion, which must also be an absolute increase of \>=200 mg/24 h:confirmed by \>=1 repeated investigation; \>25% increase in plasma cells in a bone marrow aspirate/on trephine biopsy, which must also be an absolute increase of \>= 10%; definite increase in size of existing bone lesions/soft tissue plasmacytomas; development of new bone lesions/soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \>11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause. PR: \>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size/number of lytic bone lesions.
| months | Phase 1: Isatuximab 1mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|
| Clinical Assessment: Phase 1: Duration of Response (DOR) | 20.21 | 7.16 | 5.76 ± 4.62 | 10.70 ± 11.25 | 14.31 ± 7.50 | 3.94 | 8.82 ± 7.83 |
TTR was defined as the time from first dose of isatuximab to first response (PR or better). PR: \>=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by \>=90% or \<200mg, \>=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.
| months | Phase 1: Isatuximab 1mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW |
|---|---|---|---|---|---|---|---|
| Clinical Assessment: Phase 1: Time to First Response (TTR) | 0.95 | 6.41 | 2.52 ± 3.77 | 1.96 ± 1.72 | 1.38 ± 0.65 | 1.18 | 1.46 ± 0.77 |
ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest \<50% of waking hours; 3=Bed rest/sitting \>50% of waking hours; 4=Bedridden or unable to care for self, where lower score indicated good performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the best values (categorized as: Baseline ECOG 1, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 1) are reported.
| Participants | Phase 1: Isatuximab |
|---|---|
| Baseline ECOG 1, During Treatment ECOG 0 | 11 |
| Baseline ECOG 2, During Treatment ECOG 0 | 2 |
| Baseline ECOG 2, During Treatment ECOG 1 | 11 |
ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest \<50% of waking hours; 3=Bed rest/sitting\>50% of waking hours; 4=Bedridden or unable to care for self, where higher score indicated worst performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the worst values (categorized as: Baseline ECOG 0, During Treatment ECOG 1; Baseline ECOG 2, During Treatment ECOG 1; Baseline ECOG 0, During Treatment ECOG 2; Baseline ECOG 1, During Treatment ECOG 2; Baseline ECOG 0, During Treatment ECOG 3; Baseline ECOG 1, During Treatment ECOG 3; Baseline ECOG 2, During Treatment ECOG 3) are reported.
| Participants | Phase 1: Isatuximab |
|---|---|
| Baseline ECOG 0, During Treatment ECOG 1 | 8 |
| Baseline ECOG 2, During Treatment ECOG 1 | 1 |
| Baseline ECOG 0, During Treatment ECOG 2 | 3 |
| Baseline ECOG 1, During Treatment ECOG 2 | 20 |
| Baseline ECOG 0, During Treatment ECOG 3 | 1 |
| Baseline ECOG 1, During Treatment ECOG 3 | 2 |
| Baseline ECOG 2, During Treatment ECOG 3 | 1 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.
| Participants | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W |
|---|---|---|---|---|
| Phase 2 Stage 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 22 | 24 | 25 | 25 |
AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.
| Participants | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Phase 2 Stage 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 101 | 51 |
DOR:Time from date of 1st IAC determined response (\>= PR) that was subsequently confirmed, to date of first IAC determined PD/death, whichever happened earlier. updated IMWG criteria- PR:\>=50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or a \>=50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a \>=50% reduction in size of soft tissue plasmacytomas; PD: Increase of 25% from lowest response value in any of following: Serum M-protein \>=0.5 g/dL absolute increase and/or urine M-protein \>=200 mg/24 hours absolute increase and/or \>10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, \>=10% bone marrow plasma cells (PCs), development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium \>11·5 mg/dl) attributed to PC proliferation disorder.
| months | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W |
|---|---|---|---|---|
| Phase 2 Stage 1: Duration of Response | 1.91 | 11.17 ± 5.77 | 7.31 ± 3.65 | 8.11 ± 2.33 |
DOR: Time from date of 1st IAC determined response (\>= PR) that was subsequently confirmed, to date of 1st IAC determined PD or death, whichever happened earlier. As per updated IMWG criteria-PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. ≥50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline ≥50% reduction in size of soft tissue plasmacytomas; PD: Increase of \>25% from lowest response value in any one of following: Serum M-component (absolute increase must be \>0.5 g/dL)4 and/or Urine M-component (absolute increase must be \>200 mg/24 h) and/or \>10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, \>=10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to plasma cell proliferative disorder.
| months | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Phase 2 Stage 2: Duration of Response | 8.6 ± 5.2 | 10.9 ± 4.6 |
Clinical benefit: participants with sCR, CR, VGPR, PR or MR as per IMWG criteria, determined by IAC. CR: negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytomas,\<5% PCs in bone marrow aspirates. sCR: CR + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum \& urine M-component detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-component plus urine M-component level \<100mg/24hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours, ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline, ≥50% size reduction in soft tissue plasmacytomas. MR:\>=25 but \<49% reduction in serum M-protein, reduction in 24h urine M-protein by 50-89%, 25-49% size reduction in soft tissue plasmacytomas.
| percentage of participants | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W |
|---|---|---|---|---|
| Phase 2 Stage 1: Percentage of Participants With Clinical Benefit | 4.3 | 41.7 | 32.0 | 36.0 |
Clinical benefit:participants with sCR, CR, VGPR, PR or MR, per IMWG criteria, determined by IAC. CR:negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates,normal FLC ratio(0.26-1.65) in participants with only FLC disease.sCR:CR+normal FLC ratio, absence of clonal cells in bone marrow biopsy.VGPR:serum \& urine M-component detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-component plus urine M-component level \<100mg/24h/,\>=90% decrease in difference between involved and uninvolved FLC levels; PR:\>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90%/\<200mg/24h,\>50% decrease in difference between involved and uninvolved FLC in place of M-protein criteria, \>=50% reduction in size/number of soft tissue plasmacytomas. MR:\>=25 but \<49% reduction in serum M-protein,reduction in 24h urine M-protein by 50-89%, 25-49% reduction in size of soft tissue plasmacytomas
| percentage of participants | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Phase 2 Stage 2: Percentage of Participants With Clinical Benefit | 43.1 | 54.5 |
PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression (PD) or date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of \> 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be \> 0.5 g/dL), Urine M-component and/or (the absolute increase must be \> 200 mg/24 h), \> 10mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, \>10% absolute percentage of bone marrow plasma cell, definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.
| months | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W |
|---|---|---|---|---|
| Phase 2 Stage 1: Progression Free Survival (PFS) | 2.1 (1.02 to 5.49) | 9.6 (2.23 to NA) | 4.4 (1.84 to 5.82) | 3.6 (1.91 to 9.20) |
PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression or the date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of \>25% from lowest response value in any one of the following: Serum M-component (the absolute increase must be \>0.5 g/dL)4 and/or Urine M-component (the absolute increase must be \>200 mg/24 h) and/or \>10 mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, ≥10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.
| months | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Phase 2 Stage 2: Progression Free Survival | 4.86 (3.877 to 7.688) | 10.15 (4.862 to 17.347) |
OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.
| months | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W |
|---|---|---|---|---|
| Phase 2 Stage 1: Overall Survival (OS) | 15.277 (4.7310 to NA) | 18.628 (7.7536 to 20.1068) | NA (8.4435 to NA) | NA (8.3450 to NA) |
OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.
| months | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Phase 2 Stage 2: Overall Survival | 18.92 (13.602 to 23.064) | 17.25 (15.409 to NA) |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) \& other single items. For each item, high score = high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.
| score on a scale | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W |
|---|---|---|---|---|
| Cycle 2 day 1 | -8.33 ± 20.15 | 2.22 ± 16.51 | -3.95 ± 20.67 | 0.00 ± 15.39 |
| Cycle 3 day 1 | 0.00 ± 19.25 | -0.76 ± 16.44 | 6.55 ± 19.66 | -2.08 ± 15.54 |
| Cycle 4 day 1 | 0.00 ± 24.53 | -5.30 ± 21.50 | 6.06 ± 21.11 | 7.41 ± 8.78 |
| Cycle 5 day 1 | 0.00 ± 24.53 | 0.69 ± 15.27 | 6.48 ± 21.15 | 5.00 ± 4.56 |
| Cycle 6 day 1 | 12.50 ± 14.43 | -10.19 ± 25.27 | 5.95 ± 13.36 | 10.42 ± 7.98 |
| Cycle 7 day 1 | 12.50 ± 5.89 | -3.57 ± 15.85 | 8.33 ± 11.79 | 6.67 ± 6.97 |
| Cycle 8 day 1 | 0.00 ± 35.36 | -11.11 ± 18.76 | 4.17 ± 15.96 | 6.25 ± 10.49 |
| Cycle 9 day 1 | -8.33 ± 11.79 | -10.00 ± 19.90 | 4.17 ± 14.43 | 6.25 ± 10.49 |
| Cycle 10 day 1 | -8.33 ± 35.36 | -16.67 ± 22.05 | 8.33 ± 11.79 | 3.33 ± 7.45 |
| End of treatment | 3.33 ± 33.64 | -11.67 ± 13.94 | -11.11 ± 20.97 | -12.50 ± 5.89 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with MM. It has 4 subscales: body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). Disease symptoms subscale used 4-point scale ranged from 1= 'Not at All' to 4= 'Very Much'. Scores were averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL.
| score on a scale | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W |
|---|---|---|---|---|
| Cycle 2 day 1 | 5.56 ± 18.36 | -3.42 ± 11.24 | 0.93 ± 13.91 | 2.61 ± 18.75 |
| Cycle 3 day 1 | 7.94 ± 11.94 | -5.05 ± 14.15 | -5.98 ± 16.89 | -1.52 ± 13.17 |
| Cycle 4 day 1 | 8.33 ± 13.22 | -3.89 ± 16.98 | -10.00 ± 16.93 | 0.62 ± 30.10 |
| Cycle 5 day 1 | -6.94 ± 10.52 | 0.51 ± 19.95 | -9.03 ± 17.04 | -6.67 ± 17.74 |
| Cycle 6 day 1 | 8.33 ± 7.17 | 1.23 ± 23.53 | -15.08 ± 20.96 | -6.94 ± 10.52 |
| Cycle 7 day 1 | 2.78 ± 3.93 | -3.70 ± 22.95 | -18.06 ± 21.93 | -11.11 ± 11.79 |
| Cycle 8 day 1 | -5.56 ± 7.86 | -2.78 ± 23.50 | -15.28 ± 23.30 | -4.17 ± 5.32 |
| Cycle 9 day 1 | 5.56 ± 7.86 | -10.00 ± 10.69 | -16.67 ± 29.75 | -6.94 ± 12.32 |
| Cycle 10 day 1 | 0.00 ± 0.00 | 0.00 ± 19.25 | -15.28 ± 30.56 | -6.67 ± 17.30 |
| End of treatment | -9.72 ± 19.44 | 7.78 ± 24.41 | 24.07 ± 22.45 | 25.00 ± 35.36 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.
| score on a scale | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W |
|---|---|---|---|---|
| Cycle 4 day 1 | -5.75 ± 18.55 | 2.00 ± 16.88 | -4.78 ± 15.71 | 4.89 ± 16.02 |
| Cycle 7 day 1 | -2.50 ± 0.71 | -6.00 ± 27.39 | 9.00 ± 18.25 | 1.00 ± 7.94 |
| Cycle 10 day 1 | 0.50 ± 2.12 | -10.33 ± 9.29 | 10.33 ± 24.38 | -2.60 ± 8.11 |
| Cycle 13 day 1 | 14.00 ± 19.80 | -5.00 ± 4.00 | -9.00 | -5.00 |
| Cycle 16 day 1 | 5.00 ± 5.66 | 0.67 ± 23.71 | — | — |
| Cycle 19 day 1 | — | -5.50 ± 4.95 | — | — |
| End of treatment | -18.50 ± 16.98 | -11.60 ± 11.37 | -10.00 ± 9.54 | -9.00 ± 0.00 |
| mcg*hour/mL | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 1 Week Interval | 37096 ± 80 | 35423 ± 88 |
| mcg*hour/mL | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 2 Weeks Interval | 91271 ± 78 | 86761 ± 77 |
| mcg*hour/mL | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 4 Weeks Interval | 236360 ± 72 | 226372 ± 66 |
| mcg/mL | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Day 7 | 137 ± 75 | 128 ± 54 |
| Day 14 | 230 ± 70 | 214 ± 57 |
| Day 28 | 360 ± 63 | 305 ± 66 |
Ctrough is the plasma concentration observed before treatment administration. For 1st category, the accumulation ratio was calculated by dividing Ctrough value of Cycle 2 Day 1 by Cycle 1 Day 8 and for second category, accumulation ratio was calculated by dividing Ctrough value of Cycle 4 Day 1 by Cycle 1 Day 8.
| ratio | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Cycle 2 Day 1/Cycle 1 Day 8 | 521.38338 ± 4891.63390 | 3.24370 ± 1.73860 |
| Cycle 4 Day 1/Cycle 1 Day 8 | 3.58378 ± 2.77398 | 3.95950 ± 3.19310 |
ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 2 Stage 2) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.
| Participants | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|
| Treatment induced ADA | 1 | 0 |
| Treatment boosted ADA | 0 | 0 |
Collected over All AEs were collected from signing of the informed consent form up to 30 days from last administration of study treatment (maximum exposure up to 120 weeks for Phase 1, 414 weeks for Phase 2 Stage 1a, 92 weeks for Phase 2 Stage 1b, and 301 weeks for Phase 2 Stage 2) regardless of seriousness or relationship to investigational product. All-cause mortality (Deaths) was collected for the entire study duration, 683 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Isatuximab <=1 mg/kg Q2W | 5/16 (31.3%) | 3/16 (18.8%) | 16/16 (100%) |
| Phase 1: Isatuximab 3mg/kg Q2W | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Phase 1: Isatuximab 5mg/kg Q2W | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 0/26 (0%) | 10/26 (38.5%) | 26/26 (100%) |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 2/18 (11.1%) | 10/18 (55.6%) | 18/18 (100%) |
| Phase 1: Isatuximab 10mg/kg QW | 2/6 (33.3%) | 3/6 (50%) | 6/6 (100%) |
| Phase 1: Isatuximab 20mg/kg Q2W | 2/7 (28.6%) | 3/7 (42.9%) | 6/7 (85.7%) |
| Phase 1: Isatuximab 20mg/kg QW | 0/7 (0%) | 3/7 (42.9%) | 6/7 (85.7%) |
| Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | 11/23 (47.8%) | 13/23 (56.5%) | 22/23 (95.7%) |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | 13/24 (54.2%) | 11/24 (45.8%) | 23/24 (95.8%) |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | 11/25 (44%) | 10/25 (40%) | 25/25 (100%) |
| Phase 2 Stage 1b: Isatuximab 20 mg/kg QW and Then Q2W | 11/25 (44%) | 9/25 (36%) | 24/25 (96%) |
| Phase 2 Stage 2: Isatuximab Alone | 56/109 (51.4%) | 52/109 (47.7%) | 92/109 (84.4%) |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 25/55 (45.5%) | 27/55 (49.1%) | 47/55 (85.5%) |
| Event | Phase 1: Isatuximab <=1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20 mg/kg QW and Then Q2W | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bone PainMusculoskeletal and connective tissue disorders | 0/16 | 0/6 | 1/3 | 0/26 | 1/18 | 0/6 | 0/7 | 0/7 | 0/23 | 0/24 | 0/25 | 1/25 | 1/109 | 0/55 |
| Disease ProgressionGeneral disorders | 1/16 | 0/6 | 0/3 | 0/26 | 0/18 | 0/6 | 0/7 | 0/7 | 4/23 | 0/24 | 1/25 | 1/25 | 7/109 | 2/55 |
| SepsisInfections and infestations | 0/16 | 0/6 | 0/3 | 2/26 | 1/18 | 0/6 | 0/7 | 0/7 | 4/23 | 1/24 | 0/25 | 0/25 | 3/109 | 2/55 |
| Atrial FibrillationCardiac disorders | 0/16 | 0/6 | 0/3 | 0/26 | 0/18 | 1/6 | 0/7 | 0/7 | 0/23 | 0/24 | 0/25 | 1/25 | 1/109 | 0/55 |
| Obstruction GastricGastrointestinal disorders | 0/16 | 0/6 | 0/3 | 0/26 | 0/18 | 1/6 | 0/7 | 0/7 | 0/23 | 0/24 | 0/25 | 0/25 | 0/109 | 0/55 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/16 | 0/6 | 0/3 | 0/26 | 0/18 | 1/6 | 0/7 | 0/7 | 1/23 | 0/24 | 0/25 | 0/25 | 0/109 | 2/55 |
| PyrexiaGeneral disorders | 0/16 | 1/6 | 0/3 | 0/26 | 0/18 | 0/6 | 0/7 | 0/7 | 0/23 | 0/24 | 1/25 | 0/25 | 1/109 | 1/55 |
| Abdominal SepsisInfections and infestations | 0/16 | 1/6 | 0/3 | 0/26 | 0/18 | 0/6 | 0/7 | 0/7 | 0/23 | 0/24 | 0/25 | 0/25 | 0/109 | 0/55 |
| Haemophilus SepsisInfections and infestations | 0/16 | 0/6 | 0/3 | 0/26 | 0/18 | 1/6 | 0/7 | 0/7 | 0/23 | 0/24 | 0/25 | 0/25 | 0/109 | 0/55 |
| Pneumocystis Jirovecii PneumoniaInfections and infestations | 0/16 | 0/6 | 0/3 | 0/26 | 1/18 | 1/6 | 0/7 | 0/7 | 0/23 | 0/24 | 0/25 | 0/25 | 0/109 | 0/55 |
| Event | Phase 1: Isatuximab <=1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10mg/kg QW | Phase 1: Isatuximab 20mg/kg Q2W | Phase 1: Isatuximab 20mg/kg QW | Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20 mg/kg QW and Then Q2W | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/16 | 0/6 | 2/3 | 2/26 | 1/18 | 2/6 | 0/7 | 0/7 | 6/23 | 4/24 | 2/25 | 2/25 | 11/109 | 4/55 |
| NauseaGastrointestinal disorders | 4/16 | 2/6 | 1/3 | 10/26 | 6/18 | 4/6 | 1/7 | 1/7 | 6/23 | 9/24 | 11/25 | 7/25 | 16/109 | 7/55 |
| FatigueGeneral disorders | 8/16 | 2/6 | 1/3 | 8/26 | 5/18 | 4/6 | 4/7 | 1/7 | 5/23 | 7/24 | 11/25 | 9/25 | 18/109 | 11/55 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 5/16 | 3/6 | 2/3 | 12/26 | 10/18 | 4/6 | 4/7 | 3/7 | 9/23 | 13/24 | 14/25 | 15/25 | 38/109 | 20/55 |
| Bone PainMusculoskeletal and connective tissue disorders | 2/16 | 0/6 | 2/3 | 4/26 | 3/18 | 0/6 | 0/7 | 0/7 | 1/23 | 3/24 | 1/25 | 2/25 | 10/109 | 1/55 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/16 | 1/6 | 1/3 | 7/26 | 3/18 | 3/6 | 3/7 | 1/7 | 4/23 | 7/24 | 9/25 | 6/25 | 14/109 | 8/55 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/16 | 2/6 | 1/3 | 6/26 | 2/18 | 3/6 | 1/7 | 2/7 | 2/23 | 10/24 | 7/25 | 8/25 | 19/109 | 12/55 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/16 | 1/6 | 0/3 | 4/26 | 5/18 | 1/6 | 3/7 | 0/7 | 5/23 | 5/24 | 8/25 | 4/25 | 17/109 | 7/55 |
| AnaemiaBlood and lymphatic system disorders | 6/16 | 2/6 | 0/3 | 10/26 | 4/18 | 1/6 | 0/7 | 0/7 | 9/23 | 3/24 | 8/25 | 8/25 | 4/109 | 1/55 |
| Back PainMusculoskeletal and connective tissue disorders | 1/16 | 0/6 | 1/3 | 6/26 | 7/18 | 1/6 | 0/7 | 1/7 | 2/23 | 7/24 | 3/25 | 3/25 | 20/109 | 9/55 |
Analysis was performed on AT population.
| Age, Continuous(years) | Phase 1:Isatuximab <=1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5 mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10 mg/kg QW | Phase 1: Isatuximab 20 mg/kg Q2W | Phase 1: Isatuximab 20 mg/kg QW | Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 64.9 ± 11.6 | 63.5 ± 6.2 | 62.0 ± 3.5 | 65.0 ± 7.2 | 60.8 ± 12.6 | 61.7 ± 12.7 | 63.3 ± 10.0 | 60.0 ± 8.3 | 63.2 ± 8.9 | 63.9 ± 8.8 | 61.0 ± 7.3 | 61.1 ± 10.3 | 66.6 ± 8.8 | 66.3 ± 8.9 | 64.5 ± 9.2 |
| Sex: Female, Male(Participants) | Phase 1:Isatuximab <=1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5 mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10 mg/kg QW | Phase 1: Isatuximab 20 mg/kg Q2W | Phase 1: Isatuximab 20 mg/kg QW | Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 3 | 1 | 11 | 9 | 2 | 2 | 3 | 11 | 11 | 7 | 13 | 58 | 26 | 162 |
| Male | 11 | 3 | 2 | 15 | 9 | 4 | 5 | 4 | 12 | 13 | 18 | 12 | 51 | 29 | 188 |
| Race (NIH/OMB)(Participants) | Phase 1:Isatuximab <=1 mg/kg Q2W | Phase 1: Isatuximab 3mg/kg Q2W | Phase 1: Isatuximab 5 mg/kg Q2W | Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | Phase 1: Isatuximab 10 mg/kg QW | Phase 1: Isatuximab 20 mg/kg Q2W | Phase 1: Isatuximab 20 mg/kg QW | Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W | Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | Phase 2 Stage 2: Isatuximab Alone | Phase 2 Stage 2: Isatuximab + Dexamethasone | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 3 |
| Asian | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 4 | 3 | 5 | 3 | 20 |
| White | 14 | 4 | 3 | 20 | 13 | 4 | 6 | 7 | 21 | 19 | 19 | 21 | 91 | 45 | 287 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 0 | 6 | 2 | 2 | 1 | 0 | 1 | 2 | 1 | 0 | 11 | 6 | 35 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from May 2010 to primary completion in Dec 2018, 103 months.
Results were first posted in Apr 2020, 1 year 3 months after primary completion. A results delay was requested in Dec 2019.
Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's 103 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab